Condition: Neuropathy · Urothelial Carcinoma · Metastatic Urothelial Carcinoma · Sponsor: Memorial Sloan Kettering Cancer Center
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
This description comes directly from the study's public registry record.
Samuel Funt, MD · 646-888-4770 · funts@mskcc.org
Gopakumar Iyer, MD · 646-888-4717
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activites) | Rockville Centre, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07390617